Shares of iRadimed Corp. (NASDAQ:IRMD) have been assigned a consensus broker rating score of 3.00 (Hold) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation. iRadimed Corp.’s rating score has declined by 200% from 90 days ago as a result of a number of analysts’ ratings changes.
Analysts have set a 12-month consensus target price of $11.25 for the company and are anticipating that the company will post $0.09 EPS for the current quarter, according to Zacks. Zacks has also assigned iRadimed Corp. an industry rank of 161 out of 265 based on the ratings given to related companies.
A number of research analysts have recently issued reports on IRMD shares. Zacks Investment Research downgraded iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th. Roth Capital downgraded iRadimed Corp. from a “buy” rating to a “neutral” rating and cut their price target for the company from $28.00 to $11.50 in a report on Wednesday, October 5th.
Shares of iRadimed Corp. (NASDAQ:IRMD) opened at 10.32 on Wednesday. iRadimed Corp. has a 52-week low of $9.76 and a 52-week high of $33.25. The company’s 50-day moving average price is $16.91 and its 200-day moving average price is $18.07. The stock has a market cap of $110.14 million, a PE ratio of 14.83 and a beta of 1.28.
iRadimed Corp. (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, July 29th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.03. iRadimed Corp. had a return on equity of 30.52% and a net margin of 24.52%. The business had revenue of $9.90 million for the quarter, compared to the consensus estimate of $9.60 million. During the same period last year, the business posted $0.16 EPS. The business’s revenue was up 30.3% compared to the same quarter last year. On average, equities research analysts forecast that iRadimed Corp. will post $0.92 earnings per share for the current fiscal year.
In other news, VP Steven M. Nardi sold 2,096 shares of the firm’s stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $17.11, for a total value of $35,862.56. Following the completion of the sale, the vice president now owns 1,996 shares of the company’s stock, valued at approximately $34,151.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 69.00% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the company. BlackRock Advisors LLC boosted its stake in iRadimed Corp. by 5.6% in the second quarter. BlackRock Advisors LLC now owns 8,343 shares of the company’s stock worth $182,000 after buying an additional 443 shares during the last quarter. Vanguard Group Inc. boosted its stake in iRadimed Corp. by 8.2% in the second quarter. Vanguard Group Inc. now owns 224,101 shares of the company’s stock worth $4,876,000 after buying an additional 16,888 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in iRadimed Corp. by 0.9% in the second quarter. Ameriprise Financial Inc. now owns 59,830 shares of the company’s stock worth $1,302,000 after buying an additional 530 shares during the last quarter. Mesirow Financial Investment Management Equity Management acquired a new stake in iRadimed Corp. during the second quarter worth $273,000. Finally, Oxford Asset Management boosted its stake in iRadimed Corp. by 53.5% in the second quarter. Oxford Asset Management now owns 43,742 shares of the company’s stock worth $952,000 after buying an additional 15,247 shares during the last quarter. 20.74% of the stock is owned by hedge funds and other institutional investors.
iRadimed Corp. Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for iRadimed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.